Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 339

1.

Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.

Kaya H, Bozkurt SU, Erbarut I, Djamgoz MB.

Pathol Res Pract. 2008;204(6):367-71. doi: 10.1016/j.prp.2008.01.012. Epub 2008 Mar 14.

PMID:
18342452
[PubMed - indexed for MEDLINE]
2.
3.

Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.

Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G.

Histopathology. 2005 Aug;47(2):195-201.

PMID:
16045781
[PubMed - indexed for MEDLINE]
4.

Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.

Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A.

J Pathol. 1996 May;179(1):31-8.

PMID:
8691341
[PubMed - indexed for MEDLINE]
5.

Schirrous invasive ductal carcinoma of the breast overexpress p53 oncoprotein.

Ferrini FS, Rossi MA, Neto MM, Soares FA.

Sao Paulo Med J. 2001 Jan 4;119(1):4-6.

PMID:
11175617
[PubMed - indexed for MEDLINE]
Free Article
6.

Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.

Baqai T, Shousha S.

Histopathology. 2003 May;42(5):440-7.

PMID:
12713620
[PubMed - indexed for MEDLINE]
7.

Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours.

Schmitt FC, Soares R, Seruca R.

Virchows Arch. 1998 Dec;433(6):505-9.

PMID:
9870682
[PubMed - indexed for MEDLINE]
8.

The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.

Ko SS, Na YS, Yoon CS, Park JY, Kim HS, Hur MH, Lee HK, Chun YK, Kang SS, Park BW, Lee JH.

Int J Surg Pathol. 2007 Apr;15(2):98-109.

PMID:
17478762
[PubMed - indexed for MEDLINE]
9.

Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.

Quinn CM, Ostrowski JL, Harkins L, Rice AJ, Loney DP.

Histopathology. 1998 Dec;33(6):531-6.

PMID:
9870147
[PubMed - indexed for MEDLINE]
10.
11.

Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.

Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.

Anticancer Res. 2005 May-Jun;25(3A):1719-23.

PMID:
16033090
[PubMed - indexed for MEDLINE]
Free Article
12.

Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.

Bebenek M, Bar JK, Harlozinska A, Sedlaczek P.

Anticancer Res. 1998 Jan-Feb;18(1B):619-23.

PMID:
9568187
[PubMed - indexed for MEDLINE]
13.

Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.

Honma N, Takubo K, Arai T, Younes M, Kasumi F, Akiyama F, Sakamoto G.

APMIS. 2006 Oct;114(10):712-9.

PMID:
17004974
[PubMed - indexed for MEDLINE]
14.
16.

p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.

Rudas M, Neumayer R, Gnant MF, Mittelböck M, Jakesz R, Reiner A.

Eur J Cancer. 1997 Jan;33(1):39-44.

PMID:
9071897
[PubMed - indexed for MEDLINE]
17.

C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.

Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM.

Oncol Rep. 2007 Jul;18(1):121-6.

PMID:
17549356
[PubMed - indexed for MEDLINE]
18.

Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.

Azizun-Nisa, Bhurgri Y, Raza F, Kayani N.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.

PMID:
19256737
[PubMed - indexed for MEDLINE]
Free Article
19.

Immunoexpression of HER family, neuregulin, MAPK and AKT in invasive ductal carcinomas of the breast.

Kaya H, Erbarut I, Ozkan N, Bekiroğlu N, Sen S, Abaciğlu U.

Eur J Gynaecol Oncol. 2008;29(4):350-6.

PMID:
18714568
[PubMed - indexed for MEDLINE]
20.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk